CG Oncology (CG Oncology) FCF Margin % : -4,919.47% (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. CG Oncology's Free Cash Flow for the three months ended in Mar. 2024 was $-26.02 Mil. CG Oncology's Revenue for the three months ended in Mar. 2024 was $0.53 Mil. Therefore, CG Oncology's FCF Margin % for the quarter that ended in Mar. 2024 was -4,919.47%.

As of today, CG Oncology's current FCF Yield % is -1.81%.

The historical rank and industry rank for CG Oncology's FCF Margin % or its related term are showing as below:

CGON' s FCF Margin % Range Over the Past 10 Years
Min: -22391.67 Med: -15611.52 Max: -132.76
Current: -7940.57

During the past 3 years, the highest FCF Margin % of CG Oncology was -132.76%. The lowest was -22391.67%. And the median was -15611.52%.

CGON's FCF Margin % is ranked worse than
90.52% of 1044 companies
in the Biotechnology industry
Industry Median: -139.2 vs CGON: -7940.57

CG Oncology FCF Margin % Historical Data

The historical data trend for CG Oncology's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology FCF Margin % Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

FCF Margin %

-132.76

-15,611.52

-22,391.67

CG Oncology Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial			-	-4,116.49	-	-1,606,100.00	-4,919.47

Competitive Comparison of CG Oncology's FCF Margin %

For the Biotechnology subindustry, CG Oncology's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CG Oncology's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's FCF Margin % distribution charts can be found below:

* The bar in red indicates where CG Oncology's FCF Margin % falls into.

CG Oncology FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

CG Oncology's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-45.679	/	0.204
	=	-22,391.67 %

CG Oncology's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-26.024	/	0.529
	=	-4,919.47 %

CG Oncology FCF Margin % Related Terms

Thank you for viewing the detailed overview of CG Oncology's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology (CG Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024